证券代码：600867 证券简称：通化东宝 公告编号：2025-079 通化东宝药业股份有限公司 关于门冬胰岛素注射液获得境外 药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 通化东宝药业股份有限公司（以下简称"公司"或"通化东宝"）于近日 收到多米尼加共和国公共卫生和社会福利部签发的门冬胰岛素注射液的药品注 册证书（注册证号：RM2025-1863）。现将相关情况公告如下： 一、公司产品获得境外药品注册证书情况 二、药品的其他相关情况 1 1.药品名称：门冬胰岛素注射液 2.剂型：注射剂 3.规格：3ml:300IU（每毫升 100 单位）（预填充式注射笔） 4.适应症：糖尿病 5.注册证号：RM2025-1863 6.生产厂家：通化东宝药业股份有限公司 出金额为 1,353.9 美元。公司门冬胰岛素注射液在多米尼加获批上市，将为当地 糖尿病患者提供更多的治疗选择，改善他们的治疗可及性，满足当地不断增长的 糖尿病治疗需求。 三、对公司的影响及风险提示 本次门冬胰岛素注射液获得多米尼加共和国公共卫生和社会福 ...

证券代码：600867 证券简称：通化东宝 公告编号：2025-078 通化东宝药业股份有限公司 关于以集中竞价交易方式首次回购公司股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/10/18，由董事长李佳鸿提议 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 2025 17 4 | 10 | 月 | 日~2026 | 年 | 月 | 16 | 日 | | 预计回购金额 | 2,000万元~4,000万元 | | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | 累计已回购股数 | □为维护公司价值及股东权益 143,500股 | | | | | | | | | 累计已回购股数占总股本比例 | 0.01% | | | | | | | | | 累计 ...

Corporate Announcements - China Aluminum announced the election of He Wenjian as chairman and the appointment of Zhang Ruizhong as general manager, with Zhang holding 147,100 shares of A-shares [4] - Jiangbolong reported that its self-developed main control chip deployment exceeded 100 million units by the end of Q3, with ongoing rapid growth [5] - Asia-Pacific Pharmaceutical received a notice of disapproval for the consistency evaluation application of Diltiazem Hydrochloride Tablets, which will not significantly impact current performance [6] - Fuxiang Pharmaceutical successfully passed the FDA's cGMP inspection, marking the third successful inspection, enhancing its qualification for international market supply [7] - Biaobang Co. terminated its control change planning due to failure to reach consensus on core terms, leading to stock resumption [8] - Jingjin Equipment announced the release of its actual controller and chairman from detention, allowing normal operations [9] - Sand Membrane reported that part of its fundraising account was frozen, amounting to 11.74 million yuan, related to a contract dispute [10] - Renfu Pharmaceutical's subsidiary received approval for clinical trials of HWH217 tablets for treating pulmonary arterial hypertension [12] - Wanye Enterprises will change its stock name to "Xian Dao Ji Dian" effective November 12 [13] - Huahai Pharmaceutical's subsidiary passed the FDA inspection, ensuring compliance with international standards [14] Performance Metrics - Daqin Railway reported a cargo transport volume of 32.51 million tons in October, a decrease of 4.7% year-on-year [19] - Jingji Agriculture announced sales of 233,300 pigs in October, generating revenue of 317 million yuan [20] - Baiyun Airport reported a passenger throughput of 7.64 million in October, a year-on-year increase of 12.04% [21] - Dongfeng Motor's total vehicle production decreased by 23.4% year-on-year in October, with significant declines in commercial vehicle categories [22] - Hongyang Real Estate reported a contract sales amount of 202 million yuan in October [23][24] Shareholding Changes - Xintonglian announced that a shareholder plans to reduce its stake by up to 3% [25] - Tonghua Dongbao conducted its first share buyback, acquiring 0.01% of its shares for 1.29 million yuan [26] - Guoci Materials plans to repurchase shares worth 100 million to 200 million yuan at a price not exceeding 30 yuan per share [27] - Xili Technology announced multiple shareholders plan to reduce their stakes [28] Major Contracts - Dayu Water announced a pre-bid win for a 310 million yuan water conservancy project in Hainan [29] - Zhongjian Technology signed a significant sales contract worth 563 million yuan [30] - Longjian Co. won a bid for a 441 million yuan project for road construction in Heilongjiang [31] - Chongqing Construction's subsidiary won a bid for a 781 million yuan project in Chongqing [32]

Core Viewpoint - Tonghua Dongbao announced a share buyback plan, indicating confidence in its stock value and commitment to returning capital to shareholders [1] Group 1 - The company will repurchase a total of 143,500 shares [1] - This repurchase represents 0.01% of the company's current total share capital [1] - The buyback will be conducted through centralized bidding trading [1]

Corporate Governance - China Aluminum announced the election of He Wenjian as chairman and the appointment of Zhang Ruizhong as general manager, effective immediately [3] - Jiang Guiting, the actual controller and chairman of Jingjin Equipment, has had his detention lifted, allowing him to resume his duties [8] - Biao Bang Co. has terminated its plans for a change in control, with stock resuming trading [7] Industry Developments - Jiangbolong reported that its self-developed main control chip deployment has exceeded 100 million units, with rapid growth expected [4] - Asia Pacific Pharmaceutical received a notice of disapproval for its consistency evaluation application for a drug, which will not significantly impact its current performance [5] - Fuxiang Pharmaceutical successfully passed a cGMP inspection by the FDA, marking its third successful inspection [6] - Huahai Pharmaceutical's subsidiary passed an FDA inspection, enhancing its international market capabilities [13] Financial Performance - Daqin Railway reported a cargo transport volume of 32.51 million tons in October 2025, a year-on-year decrease of 4.7% [18] - Jingji Zhino achieved sales revenue of 317 million yuan from selling 233,300 pigs in October 2025 [19] - Baiyun Airport reported a passenger throughput of 7.64 million in October 2025, a year-on-year increase of 12.04% [20] - Dongfeng Motor's total vehicle production in October 2025 was 6,536 units, a year-on-year decrease of 23.40% [21] - Hongyang Real Estate reported a contract sales amount of 202 million yuan in October 2025 [22] Shareholder Actions - Xintonglian announced that a shareholder plans to reduce its stake by up to 3% [24] - Tonghua Dongbao conducted its first share buyback, acquiring 143,500 shares for 1.29 million yuan [25] - Guoci Materials plans to repurchase shares worth 100 million to 200 million yuan at a price not exceeding 30 yuan per share [26] Project Wins - Dayu Water-saving announced a pre-bid win for a 310 million yuan water conservancy project in Hainan [28] - Zhongjian Technology signed a significant sales contract worth 563 million yuan [29] - Longjian Co. won a project bid worth 441 million yuan for road construction in Heilongjiang [30] - Chongqing Construction's subsidiary won a project bid worth 781 million yuan for a residential project in Chongqing [31]

Group 1 - Company announced a share repurchase of approximately 140,000 shares, representing 0.01% of the total share capital, at a price range of 9 CNY per share, with a total transaction amount of approximately 1.29 million CNY [1] - For the first half of 2025, the company's revenue composition was 98.59% from the pharmaceutical industry, 1.27% from other businesses, and 0.14% from the real estate sector [1] - The current market capitalization of the company is 17.7 billion CNY [1]

Group 1 - The company, Tonghua Dongbao (600867.SH), announced its first share repurchase on November 6, 2025, through centralized bidding [1] - A total of 143,500 shares were repurchased, accounting for 0.01% of the company's current total share capital [1] - The highest and lowest transaction prices for the repurchase were both 9.00 yuan per share, with a total transaction amount of 1.2915 million yuan (excluding transaction fees) [1]

通化东宝公告，公司于2025年11月6日首次通过集中竞价交易方式回购公司股份，累计回购股数为14.35 万股，占公司总股本的0.01%，累计回购金额为129.15万元，实际回购价格为9元/股。此次回购将用于 员工持股计划或股权激励。 ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 67.2 yuan based on a 28x PE valuation for 2026 [3][5]. Core Insights - The company continues to show strong growth, with a revenue of 30.5 billion yuan in the first three quarters of 2025, representing a year-on-year increase of 35.7%. The net profit attributable to the parent company reached 8.2 billion yuan, up 61.3% year-on-year [10]. - The company's domestic insulin sales reached 26.2 billion yuan, growing by 45.6% year-on-year, driven by the effects of price recovery following the renewal of insulin procurement [10]. - The company has made significant strides in emerging markets, particularly in Brazil, where it signed a major contract worth no less than 3 billion yuan over ten years for a public health project [10]. Financial Performance Summary - Revenue projections for 2025-2027 are 42.02 billion yuan, 51.81 billion yuan, and 61.15 billion yuan, respectively, with year-on-year growth rates of 38.0%, 23.3%, and 18.0% [8]. - The net profit attributable to the parent company is forecasted to be 1.14 billion yuan, 1.43 billion yuan, and 1.70 billion yuan for 2025-2027, with growth rates of 85.6%, 25.8%, and 18.3% [8]. - The gross margin is expected to improve to 78.7% in 2025, with a net margin of 27.1% [8].

Company Overview - Tonghua Dongbao Pharmaceutical Co., Ltd. is located in Tonghua County, Jilin Province, established on December 28, 1992, and listed on August 24, 1994 [1] - The company's main business includes hard capsule preparations, tablets (including hormone types), granules, small-volume injections, raw materials (recombinant human insulin), and biological engineering products (recombinant human insulin injection) [1] Financial Performance - For the period from January to September 2025, Tonghua Dongbao achieved operating revenue of 2.18 billion yuan, a year-on-year increase of 50.55% [2] - The net profit attributable to the parent company was 1.20 billion yuan, showing a significant year-on-year growth of 1911.35% [2] Stock Market Activity - As of November 4, the stock price of Tonghua Dongbao was 9.08 yuan per share, with a market capitalization of 17.78 billion yuan [1] - The stock has increased by 16.23% year-to-date, with a 2.02% rise over the last five trading days and a 9.79% increase over the last 20 days [1] Shareholder Information - As of September 30, 2025, the number of shareholders was 82,100, a decrease of 5.08% from the previous period [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 15.84 million shares [3] Dividend Distribution - Since its A-share listing, Tonghua Dongbao has distributed a total of 5.51 billion yuan in dividends, with 1.48 billion yuan distributed in the last three years [3]